https://charts.traderzeitung.de/phases/US02081G2012
string(1427) "{"isin":"US02081G2012","name":"Alphatec Holdings Inc","stock_id":7873161,"generated_at":"2026-10-06 08:46:00","days":[{"date":"2026-10-01","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.905,"close_at":"2026-10-01 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":9.9,"close_at":"2026-10-01 22:00:00","complete":true,"perf_pct":-0.0505}]},{"date":"2026-10-02","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":10.04,"close_at":"2026-10-02 21:59:00","complete":true,"perf_pct":1.4141},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":10,"close_at":"2026-10-05 14:43:00","complete":true,"perf_pct":-0.3984},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":10.715,"close_at":"2026-10-05 21:59:00","complete":true,"perf_pct":7.15},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":10.72,"close_at":"2026-10-05 22:00:00","complete":true,"perf_pct":0.0467}]}]}"
Alphatec Holdings Aktie News & Nachrichten

Alphatec Holdings Aktie News & Nachrichten

[WKN: A2AP5V | Symbol: ATEC]
Realtimekurs
   

Alphatec Holdings (ATEC): Bis 2025 könnten zweistellige EBITDA-Margen erzielt werden - Barclays sieht 137 % Kurspotenzial

Alphatec Holdings Inc. (ATEC) ist ein Medizintechnikunternehmen, das sich auf die Entwicklung und Verbesserung...

TOP-5-Kursziele der Analysten am 19.11.24

Aclaris Therapeutics [US00461U1051]: BTIG nimmt Hochstufung von "Hold" auf "Buy" mit Kursziel 8 USD vor...

TOP-5-Kursziele der Analysten am 05.11.24

Disc Medicine Inc. [US2546041011]: Raymond James nimmt ein Hochstufung von "Outperform" auf "Strong Buy"...